Management of multiple sclerosis patients in central European countries: current needs and potential solutions

Thomas Berger, Monika Adamczyk-Sowa, Tünde Csépány, Franz Fazekas, Tanja Hojs Fabjan, Dana Horáková, Zsolt Illes, Eleonóra Klimová, Fritz Leutmezer, Konrad Rejdak, C. Rózsa, Saša Šega Jazbec, Jarmila Szilasiová, Peter Turčáni, Marta Vachová, L. Vécsei, Eva Havrdová

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Multiple sclerosis (MS) experts in Europe are facing rapidly rising demands of excellence due to the increasing complexity of MS therapy and management. A central European expert board of MS experts met to identify needs and obstacles with respect to raising quality of MS care in central and Eastern European countries. There are substantial variations across countries regarding delivery of care and its cost structure, as well as access to treatment. To date, Eastern European countries are often less able to afford reimbursement of immunomodulatory agents than Western countries. Overall, approximately 40% of working-age patients are not working due to MS. Costs rise steeply with increasing disability; indirect costs constitute the bulk of the financial burden in patients with severe MS. Magnetic resonance imaging (MRI) assessment is meanwhile obligatory as the diagnostic interface in the management of MS patients. Recommended measures directed at improving quality of care include the collection of patient data in registries, enhanced education of healthcare professionals, implementation of national strategies aiming at reducing regional variation, optimization of approval processes, and removal of administrative barriers. Local partnerships with authorities such as those that represent the interests of employees can contribute to leverage the importance of epidemiological data. The need for education extends to (neuro)radiologists who are responsible for reporting MRI findings in expert quality. Dissemination of the Magnetic Resonance Imaging in MS (MAGNIMS) protocol would be an important step in this context. Also, clinical freedom of choice is rated as essential. Physicians should have access to a range of treatment options due to the complexity of disease. Guidelines such as the upcoming EAN-ECTRIMS clinical practice guideline also aim at providing a basis for argumentation in negotiations with national health authorities.

Original languageEnglish
JournalTherapeutic Advances in Neurological Disorders
Volume11
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Multiple Sclerosis
Magnetic Resonance Imaging
Costs and Cost Analysis
Professional Education
Quality of Health Care
Negotiating
Practice Guidelines
Registries
Therapeutics
Guidelines
Delivery of Health Care
Physicians
Education
Health

Keywords

  • access to treatment
  • burden of disease
  • MS registry
  • multiple sclerosis
  • quality of care

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology

Cite this

Management of multiple sclerosis patients in central European countries : current needs and potential solutions. / Berger, Thomas; Adamczyk-Sowa, Monika; Csépány, Tünde; Fazekas, Franz; Hojs Fabjan, Tanja; Horáková, Dana; Illes, Zsolt; Klimová, Eleonóra; Leutmezer, Fritz; Rejdak, Konrad; Rózsa, C.; Šega Jazbec, Saša; Szilasiová, Jarmila; Turčáni, Peter; Vachová, Marta; Vécsei, L.; Havrdová, Eva.

In: Therapeutic Advances in Neurological Disorders, Vol. 11, 01.01.2018.

Research output: Contribution to journalReview article

Berger, T, Adamczyk-Sowa, M, Csépány, T, Fazekas, F, Hojs Fabjan, T, Horáková, D, Illes, Z, Klimová, E, Leutmezer, F, Rejdak, K, Rózsa, C, Šega Jazbec, S, Szilasiová, J, Turčáni, P, Vachová, M, Vécsei, L & Havrdová, E 2018, 'Management of multiple sclerosis patients in central European countries: current needs and potential solutions', Therapeutic Advances in Neurological Disorders, vol. 11. https://doi.org/10.1177/1756286418759189
Berger, Thomas ; Adamczyk-Sowa, Monika ; Csépány, Tünde ; Fazekas, Franz ; Hojs Fabjan, Tanja ; Horáková, Dana ; Illes, Zsolt ; Klimová, Eleonóra ; Leutmezer, Fritz ; Rejdak, Konrad ; Rózsa, C. ; Šega Jazbec, Saša ; Szilasiová, Jarmila ; Turčáni, Peter ; Vachová, Marta ; Vécsei, L. ; Havrdová, Eva. / Management of multiple sclerosis patients in central European countries : current needs and potential solutions. In: Therapeutic Advances in Neurological Disorders. 2018 ; Vol. 11.
@article{dfb12008fa3e4dc0b5a5c0daa5ede324,
title = "Management of multiple sclerosis patients in central European countries: current needs and potential solutions",
abstract = "Multiple sclerosis (MS) experts in Europe are facing rapidly rising demands of excellence due to the increasing complexity of MS therapy and management. A central European expert board of MS experts met to identify needs and obstacles with respect to raising quality of MS care in central and Eastern European countries. There are substantial variations across countries regarding delivery of care and its cost structure, as well as access to treatment. To date, Eastern European countries are often less able to afford reimbursement of immunomodulatory agents than Western countries. Overall, approximately 40{\%} of working-age patients are not working due to MS. Costs rise steeply with increasing disability; indirect costs constitute the bulk of the financial burden in patients with severe MS. Magnetic resonance imaging (MRI) assessment is meanwhile obligatory as the diagnostic interface in the management of MS patients. Recommended measures directed at improving quality of care include the collection of patient data in registries, enhanced education of healthcare professionals, implementation of national strategies aiming at reducing regional variation, optimization of approval processes, and removal of administrative barriers. Local partnerships with authorities such as those that represent the interests of employees can contribute to leverage the importance of epidemiological data. The need for education extends to (neuro)radiologists who are responsible for reporting MRI findings in expert quality. Dissemination of the Magnetic Resonance Imaging in MS (MAGNIMS) protocol would be an important step in this context. Also, clinical freedom of choice is rated as essential. Physicians should have access to a range of treatment options due to the complexity of disease. Guidelines such as the upcoming EAN-ECTRIMS clinical practice guideline also aim at providing a basis for argumentation in negotiations with national health authorities.",
keywords = "access to treatment, burden of disease, MS registry, multiple sclerosis, quality of care",
author = "Thomas Berger and Monika Adamczyk-Sowa and T{\"u}nde Cs{\'e}p{\'a}ny and Franz Fazekas and {Hojs Fabjan}, Tanja and Dana Hor{\'a}kov{\'a} and Zsolt Illes and Eleon{\'o}ra Klimov{\'a} and Fritz Leutmezer and Konrad Rejdak and C. R{\'o}zsa and {Šega Jazbec}, Saša and Jarmila Szilasiov{\'a} and Peter Turč{\'a}ni and Marta Vachov{\'a} and L. V{\'e}csei and Eva Havrdov{\'a}",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/1756286418759189",
language = "English",
volume = "11",
journal = "Therapeutic Advances in Neurological Disorders",
issn = "1756-2856",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Management of multiple sclerosis patients in central European countries

T2 - current needs and potential solutions

AU - Berger, Thomas

AU - Adamczyk-Sowa, Monika

AU - Csépány, Tünde

AU - Fazekas, Franz

AU - Hojs Fabjan, Tanja

AU - Horáková, Dana

AU - Illes, Zsolt

AU - Klimová, Eleonóra

AU - Leutmezer, Fritz

AU - Rejdak, Konrad

AU - Rózsa, C.

AU - Šega Jazbec, Saša

AU - Szilasiová, Jarmila

AU - Turčáni, Peter

AU - Vachová, Marta

AU - Vécsei, L.

AU - Havrdová, Eva

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Multiple sclerosis (MS) experts in Europe are facing rapidly rising demands of excellence due to the increasing complexity of MS therapy and management. A central European expert board of MS experts met to identify needs and obstacles with respect to raising quality of MS care in central and Eastern European countries. There are substantial variations across countries regarding delivery of care and its cost structure, as well as access to treatment. To date, Eastern European countries are often less able to afford reimbursement of immunomodulatory agents than Western countries. Overall, approximately 40% of working-age patients are not working due to MS. Costs rise steeply with increasing disability; indirect costs constitute the bulk of the financial burden in patients with severe MS. Magnetic resonance imaging (MRI) assessment is meanwhile obligatory as the diagnostic interface in the management of MS patients. Recommended measures directed at improving quality of care include the collection of patient data in registries, enhanced education of healthcare professionals, implementation of national strategies aiming at reducing regional variation, optimization of approval processes, and removal of administrative barriers. Local partnerships with authorities such as those that represent the interests of employees can contribute to leverage the importance of epidemiological data. The need for education extends to (neuro)radiologists who are responsible for reporting MRI findings in expert quality. Dissemination of the Magnetic Resonance Imaging in MS (MAGNIMS) protocol would be an important step in this context. Also, clinical freedom of choice is rated as essential. Physicians should have access to a range of treatment options due to the complexity of disease. Guidelines such as the upcoming EAN-ECTRIMS clinical practice guideline also aim at providing a basis for argumentation in negotiations with national health authorities.

AB - Multiple sclerosis (MS) experts in Europe are facing rapidly rising demands of excellence due to the increasing complexity of MS therapy and management. A central European expert board of MS experts met to identify needs and obstacles with respect to raising quality of MS care in central and Eastern European countries. There are substantial variations across countries regarding delivery of care and its cost structure, as well as access to treatment. To date, Eastern European countries are often less able to afford reimbursement of immunomodulatory agents than Western countries. Overall, approximately 40% of working-age patients are not working due to MS. Costs rise steeply with increasing disability; indirect costs constitute the bulk of the financial burden in patients with severe MS. Magnetic resonance imaging (MRI) assessment is meanwhile obligatory as the diagnostic interface in the management of MS patients. Recommended measures directed at improving quality of care include the collection of patient data in registries, enhanced education of healthcare professionals, implementation of national strategies aiming at reducing regional variation, optimization of approval processes, and removal of administrative barriers. Local partnerships with authorities such as those that represent the interests of employees can contribute to leverage the importance of epidemiological data. The need for education extends to (neuro)radiologists who are responsible for reporting MRI findings in expert quality. Dissemination of the Magnetic Resonance Imaging in MS (MAGNIMS) protocol would be an important step in this context. Also, clinical freedom of choice is rated as essential. Physicians should have access to a range of treatment options due to the complexity of disease. Guidelines such as the upcoming EAN-ECTRIMS clinical practice guideline also aim at providing a basis for argumentation in negotiations with national health authorities.

KW - access to treatment

KW - burden of disease

KW - MS registry

KW - multiple sclerosis

KW - quality of care

UR - http://www.scopus.com/inward/record.url?scp=85054862551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054862551&partnerID=8YFLogxK

U2 - 10.1177/1756286418759189

DO - 10.1177/1756286418759189

M3 - Review article

AN - SCOPUS:85054862551

VL - 11

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

SN - 1756-2856

ER -